Pluristem Therapeutics (PSTI) receives FDA orphan status for aplastic anemia treatment
- Market Wrap: FOMC Tapers Further; Q2 GDP Outpaces Expectations; U.S. Job Growth Lags in July
- After-Hours Stock Movers 7/30: (MOBL) (VPRT) (LPSN) Higher; (EHTH) (ATEN) (GLUU) Lower (more...)
- Yelp (YELP) Tops Q2 EPS by 7c; Issues Solid Outlook
- Whole Foods Market, Inc. (WFM) Tops Q3 EPS by 2c; Comps Growth Lighter than Expected
- S&P Cuts Argentina to 'SD' from 'CCC-/C'
Pluristem Therapeutics, Inc. (NASDAQ: PSTI) has received FDA orphan status for aplastic anemia treatment.
You May Also Be Interested In
- UPDATE: Impax Laboratories (IPXL) Issued Form 483 Following FDA Inspection of Taiwan Facility
- Sony Doesn't See EA Access as 'Good Value' for PS4 Customers (MSFT) (GME) (EA)
- Top 10 Trending Stocks for 07/30: Twitter (TWTR), Amgen (AMGN), Regeneron (REGN), and More...
Create E-mail Alert Related CategoriesFDA, Insiders' Blog
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!